Airedale Hospital COVID study is reported in global medical journal
Airedale NHS Foundation Trust has been mentioned in the renowned New England Journal of Medicine, as one of the hospitals involved in trials of a drug which aims to help patients with severe COVID-19 symptoms.
Dexamethasone was one of the patient treatments tested at part of the nationwide RECOVERY trial that is seeking drugs and treatments which can reduce the mortality rate of COVID-19.
Recent results from the trial have shown that Dexamethasone can significantly improve outcomes for some of the most severely ill hospitalised patients.
The Airedale NHS Foundation Trust Research team have been involved in enrolling patients to the RECOVERY trial and have been highlighted as one of the 175 NHS organisations in the UK that were part of the successful Dexamethasone study, which has now been published.
At Airedale, the principal investigator for the RECOVERY trial was ICU consultant Dr Tamsin Gregory who worked alongside senior research sister Emma Dooks and other members of the research team.
A total of 19 patients have so far been recruited to the study at Airedale and thousands were recruited across the country.
Emma Dooks said, “It was a privilege to be part of this national research trial, and we are proud that this work has been acknowledged in this prestigious global medical publication. I’m so pleased that there has been a breakthrough and we can now use these positive results to treat coronavirus patients and manage the pandemic going forward. Thank you to each and every one of the patients who took part – your involvement will help to save lives.”
You can read the report in the New England Journal of Medicine here https://www.nejm.org/doi/10.1056/NEJMoa2021436